There is an interesting discussion on SH from Ronrydel, BDAZ's response (keep this one in your file), jkj and GV.

It seems to me that there is a very interesting sub-text in the CEPT story. Big pharmas and organizations with esteemed researchers have invested enormous amounts money and time behind the concept of CEPT inhibitors. Bear said many scieintists have written CEPT inhibitors off years ago and yet BP continues with huge trials even though results have show no significant MACE impacts even on 5 point MACE.

BDAZ - from SH

Apabetalone stimulates the synthesis of new apolipoprotein-AI and new HDL particles....a totally different effect on HDL metabolism compared to CETP inhibitors. Plus, apabetalone's beneficial effects on cardiovascular biomarkers extend beyond HDL, including effects on inflammation (high-sensitivity C-reactive protein, IL6, MCP1), alkaline phosphatase, calcification and components of the complement and coagulation cascades. So apabetalone doesn't rely entirely on it's HDL modulating effects.
Read more at http://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#1JLxsmWCOsUujzjF.99

Are you suggesting that the failure of CETP inhibitors impact the likelihood of BETonMACE successfully meeting its endpoints? As described above, these drugs have very little in common other than both modulating HDL...albeit in two totally different ways. New apo-AI synthesis and new HDL particle formation is distinct from CETP-inhibition mediated increase in HDL-cholesterol. This latter CETP effect has been sometimes referred to as creating garbage bags of HDL-cholesterol......meaning it is not very active/useful in providing the cardioprotective effects of HDL. Do we have to wait another year for BETonMACE to be finished? Yes. Will we get similarly negative results as provided by CETP cardiovascular outcomes trials? In my opinion, no way. That's why I'm still invested here. 
Read more at http://www.stockhouse.com/companies/bullboard/t.rvx/resverlogix-corp#1JLxsmWCOsUujzjF.99

My point is that large institutions tend to get hung up and a certain theory while it appears, at least to my knowledge, none of them are buying into BETi. Hence, our marvelous little Calgary biotech may be a trojan horse about to deliver a very big surprise. Let's have a successful 3 point MACE futility analysis and we'll be one step closer. Perhaps failure of CEPT inhibitors will focus some attention on RVX.

Let's hope so.

Toinv